Myopia control in Malaysia: what slows a child's short-sightedness, what does not, and when to start

Draft, awaiting Dr Chan's sign-off

Every clinical statement on this page is traced to a fetched source in research/clinical-facts-3.md, but the page has not yet been reviewed and signed by Dr Chan Li Yen. Until this notice is gone it is a working draft, not published advice.

Key takeaways

Nothing reverses a child's short-sightedness. Myopia control means slowing how fast it climbs, so the final prescription and the lifetime risk end lower.
Four treatments have trial evidence for slowing it: low-dose atropine drops, myopia-control spectacle lenses, myopia-control soft contact lenses, and overnight rigid lenses. All are prescribed and monitored; none is a product to shop for.
Atropine strengths are a fraction of the full-strength drop: 0.01, 0.025 and 0.05 percent. Stronger slows more with slightly more side effects; the strength is the doctor's choice with you, not a brand choice.
Time outdoors has good evidence for delaying the start of myopia and weak evidence for slowing it once it has begun. Blue-light glasses, eye exercises and supplements have no trial evidence for slowing it.
In Malaysia the public route runs through a referral to a government hospital eye clinic; the private route is booked directly. Ask for a written estimate before any treatment starts.

The conversation usually starts at the optical shop. Your child's "power" has gone up again, someone has mentioned special lenses or drops, a figure has been quoted, and you have come home with a leaflet and no way of telling how much of it is evidence. This page is the map I would draw for you across the desk. It covers what has been shown in trials to slow short-sightedness, what has not, when it is worth starting, and how the public and private routes work in Malaysia. It does not name products, because the treatments are classes, not brands, and because which one suits your child is a decision for the appointment, not for a page.

Two words before we start. Short-sightedness, myopia, is the eye growing slightly too long for its own focusing power, so distance blurs while near stays sharp. "Progression" is that growth continuing year on year through childhood, the yearly climb in the prescription. Everything below is about slowing that climb. Nothing below reverses it.

What is myopia control, and what can it honestly do?

It is a small group of treatments that slow how fast a child's short-sightedness worsens. It cannot undo the short-sightedness already there. Once the eye has grown to the point of blurring the distance, that length does not shrink back, and any clinic or shop that promises to reverse or cure a child's myopia is promising something no treatment has been shown to do.

The honest goal is a lower final prescription than the child would otherwise have reached, and a lower lifetime risk of the eye problems that come with a very long eye. That is a smaller promise than "fixing" it, and it is a real one. I have written about why so many children are short-sighted now; this page is the next step, for the family that has been told the number is climbing.

Why does slowing it matter, if glasses fix the blur anyway?

Because glasses correct the blur but not the length of the eye, and it is the length that carries the long-term risk. A very short-sighted eye is a stretched eye, and stretched retinas and stretched supporting layers are more prone to trouble later in life.

The clinical statement of the American Academy of Ophthalmology puts numbers on it: compared with an eye that is not short-sighted, a prescription between about minus one and minus three carries roughly four times the risk of a retinal detachment, and beyond minus three roughly ten times. High myopia is also linked with glaucoma, cataract and a form of damage to the central retina called myopic maculopathy. None of that is a reason to panic about a child in minus two glasses. It is the reason a doctor takes a fast-climbing prescription seriously rather than simply writing a stronger one each year.

Does time outdoors slow it down?

It has good evidence for delaying the start of short-sightedness, and weaker evidence for slowing it once it has begun. That distinction is the single most useful thing on this page, and it is often blurred in advertising.

In the research pooled by the Academy's task force, each extra hour a child spent outdoors per week was linked with about two percent lower odds of becoming short-sighted, and the practical target eye doctors quote is roughly one to two hours outside a day. For a child who is already myopic, most studies have not found that outdoor time slows the climb. So: get the younger siblings outside, because it may spare them the problem, and keep the short-sighted child outside too, because it is good for a great deal else and it costs nothing, but do not rely on it alone to hold the prescription. Habits like screen breaks help comfort; they are not on the list of things shown to slow progression.

What are low-dose atropine drops, and what do 0.01 and 0.025 percent mean?

They are a class of prescription eye drops, a drop in each eye at bedtime, used for years, that slow the growth of the eye; they currently carry the strongest trial evidence of the treatments on this page. Atropine is an old medicine. At full strength, one percent, it is the long-acting drop used to widen the pupil for some examinations, and its effect on the pupil and on near focus lasts far longer than the everyday check-up drops.

Myopia control uses a fraction of that. The number on the bottle is grams of atropine in every hundred millilitres, so 0.01 percent is one hundredth of the full-strength drop, and even the strongest of the three studied, 0.05 percent, is a twentieth of it. The largest trial comparing those three strengths followed 438 children aged four to twelve for a year. The placebo group's prescription moved by about 0.81 dioptres. On 0.01 percent it moved by about 0.59, on 0.025 percent by about 0.46, and on 0.05 percent by about 0.27. The eye grew least on the strongest drop, and pupil size and near focusing were affected a little more as the strength rose. Vision and day-to-day quality of life were not affected at any of the three.

What that means for your child is a choice of strength, not a choice of brand, and it is the doctor's to make with you. A stronger drop slows more and is a little more likely to cause light sensitivity or near blur. A weaker one is gentler and slows less. The older trials also found that a lower strength produced less "rebound", the catch-up in progression that can follow stopping. The drops are used every night for two to three years or more, with regular reviews of the prescription and, where the clinic measures it, the length of the eye. Side effects at these strengths are usually mild: some redness or itchiness around the eye, some light sensitivity, a slightly larger pupil, occasionally near blur.

Two things worth being clear about. These are prescription drops, prescribed and monitored by a doctor, not something to source yourself. And stopping them suddenly is a decision to make at a review, not at home, because of that rebound.

What are myopia-control spectacle lenses?

Ordinary-looking glasses whose lens does two jobs at once: the centre corrects distance the way any lens does, and the surrounding zone is built to blur the edge of vision slightly, a signal that appears to slow the eye's growth. Trials of this design show a real but modest slowing, and the best results came with the glasses worn full time during waking hours; a lens that lives in the school bag does nothing.

In the United States a design of this kind is approved for children aged six to twelve, which gives you a sense of the age band the evidence covers. Older bifocal and progressive lenses, the kind adults wear for reading, slowed progression by so little in trials that the researchers concluded it did not justify a change in practice. If your child is at the age of a first pair, what happens after a child is prescribed glasses covers the getting-used-to-them part; the myopia-control question is a separate one to raise at the review.

What about contact lenses: overnight lenses and myopia-control soft lenses?

Two different lenses, one shared caveat. Overnight hard contact lenses, orthokeratology or ortho-k, are worn while the child sleeps and gently flatten the front of the eye so that they see clearly without glasses by day, and in trials they also slow the eye's growth. Soft myopia-control lenses are worn by day and work on the same edge-of-vision principle as the spectacle lenses above; the evidence for them sits in children of about eight to twelve, and they do not work for every child.

The shared caveat is infection. Any contact lens carries a risk of infection of the cornea, the clear front window of the eye, and overnight wear carries a considerably higher risk than daytime wear, of an infection that can scar the cornea and, at worst, cost sight. That is why these options need a child old enough to handle a lens cleanly, a family able to keep to the routine, and more follow-up visits than the other options. For the right family they are a good choice. They are not a shortcut.

What does not slow short-sightedness?

Anything not on the list above. That sounds blunt, but it is the fairest test I can give you, because the list of treatments with trial evidence is short and everything else is being sold on hope. Blue-light glasses are the commonest: there is no scientific evidence that the light from screens damages children's eyes, and blue-light lenses are not a myopia-control treatment. Eye exercises, vision-training programmes and supplements do not appear on that list, and I know of no trial showing that any of them slows the growth of the eye.

Wearing weaker glasses than prescribed, or none at all, is sometimes suggested as a way to "rest" the eye; it is not a treatment on that list either, and it leaves a child seeing badly in the meantime. Nor does avoiding glasses "to stop dependence": glasses do not weaken a child's eyes, and that myth and its cousins get a fuller airing in children's eye myths. And screens: sitting close and reading a lot are part of the modern-childhood picture, and I discuss what closeness does and does not mean in why children sit so close to the screen, but the evidence tying near work to short-sightedness is inconsistent. Limit screens for the reasons that hold anyway, comfort and sleep, and do not pay anyone who sells a screen habit as treatment.

When should myopia control start, and who decides?

Once a child is confirmed short-sighted by a proper measurement, and especially once the prescription is seen to be climbing, with the strongest reason to act in the youngest children. A child who becomes short-sighted at six has far more growing years ahead than one who becomes short-sighted at twelve, so the same yearly climb ends somewhere very different. That is why an early start is the pattern in the trials: the atropine study above enrolled children from four, and the American Academy of Ophthalmology lists the drops for ages five to eighteen, the spectacle lenses for six to twelve, and the soft lenses for eight to twelve.

The measurement matters as much as the age. A child's true prescription is measured with drops that relax the focusing muscle, because children can over-focus and hide the real number, and a shop reading taken without those drops can overstate the short-sightedness. From there, the decision is a conversation with an eye doctor who sees children: how fast is it moving, how old is the child, what does the family's routine make realistic, and which option carries side effects you can live with. Progress is then followed by repeating that measurement, and where the clinic can, measuring the length of the eye, at regular reviews.

Public or private: what are the routes in Malaysia, and what do the rules say about cost?

There are two doors, and many families use both. The public route runs through a klinik kesihatan or GP, who refers your child to the eye clinic of a Ministry of Health hospital. School vision screening in Malaysia generally begins in primary school, so the preschool years are the parent's to watch. Government hospital charges for Malaysian citizens are set by law and are small. The state hospital charge pages list a registration fee of RM1 for a general outpatient visit. A specialist clinic visit is RM5. A first specialist visit is RM30 if you come with a private clinic's referral rather than a government one. Bring the referral letter and any previous prescriptions.

The private route is an eye clinic that sees children, booked directly. Here too the consultation fee is regulated: the Thirteenth Schedule of the Private Healthcare Facilities and Services Act sets the specialist consultation fee for private hospitals and similar facilities in a range from RM80 to RM235, unchanged since 2013. That range covers the consultation.

The drops, the spectacle lenses, the contact lenses and the extra tests are charged separately, and I am not going to quote figures for them here: they differ from clinic to clinic and change over time, and a figure on a page like this would either mislead you or be unfair to someone. Ask any clinic for a written estimate before you start, and ask what the follow-up visits will cost. Optometrists share this work: they measure and dispense spectacles and contact lenses, including the myopia-control designs, while prescribing the drops and examining the health of the eye is the doctor's part.

One local fact worth knowing, because it tells you this is being studied seriously here rather than imported on trust. A randomised trial called ATOM-MY, registered on the public ClinicalTrials.gov registry as NCT07329777, is recruiting children aged five to ten at two university hospitals in Kuala Lumpur to compare 0.025 percent atropine drops with placebo, with a two-year follow-up and its first results not due before 2027. It has no results yet, and it is a study rather than a service; I mention it as a registry fact, not as something to seek out through this page.

See an eye doctor sooner if…

Your child's prescription is climbing quickly between checks, or your child became short-sighted young, in the early primary-school years or before.
Your child squints, sits ever closer, rubs their eyes, or complains of headaches or blur despite up-to-date glasses.
A short-sighted child sees sudden flashes, a shower of new floaters, or a shadow or curtain across their vision: that is a same-day emergency, not a review.
You have been offered a treatment that promises to reverse or cure short-sightedness. Nothing does, and it is worth a proper opinion before you pay.

Common questions

Can my child's short-sightedness be reversed?

No. Once the eye has grown long enough to blur the distance, that length does not shrink back, and no treatment has been shown to undo it. What can be done is to slow the yearly climb, which is a real and useful goal: a lower final prescription and a lower lifetime risk of retinal problems. Be wary of anyone who promises more than that.

Which atropine strength is best: 0.01, 0.025 or 0.05 percent?

There is no single best strength, which is why the choice is made at the appointment rather than by a page. In the trial that compared all three over a year, the stronger drop slowed the climb more and affected pupil size and near focusing a little more; the weaker drop was gentler, slowed less, and in earlier studies produced less rebound when stopped. Age, how fast the prescription is moving, and how your child copes with light sensitivity all feed into the choice.

Are low-dose atropine drops safe to use for years?

At these strengths the side effects reported in trials have been mild: some redness or itchiness around the eye, some light sensitivity, a slightly larger pupil, occasionally near blur, and in the year-long comparison of three strengths neither vision nor day-to-day quality of life was affected. They are prescription drops used every night for two to three years or longer, with regular reviews. Do not stop them abruptly on your own, because progression can catch up after stopping; make that decision at a review.

Can I just get myopia-control lenses at the optical shop without seeing a doctor?

The spectacle and soft contact lenses are dispensed by optometrists, so in practice many families start there. What I would ask is that the decision rests on a proper measurement first: a child's true prescription is measured with drops that relax the focusing muscle, and a shop reading taken without them can mislead. Whether your child needs myopia control at all, and whether drops, lenses or both suit them, is a conversation for an eye doctor who sees children, and the two professions work best together.

Is orthokeratology (overnight lenses) safe for a child?

It slows the eye's growth in trials, and it lets a child see clearly by day without glasses, but overnight lens wear carries a considerably higher risk of infection of the clear front of the eye than daytime wear, and that infection can scar and, at worst, cost sight. So it suits a child old enough to handle a lens cleanly, a family who can keep to the routine, and a clinic that will see you often. It is a good option for the right family, and it is not a shortcut.

Do blue-light glasses help slow short-sightedness?

No. There is no scientific evidence that the light from screens damages children's eyes, and blue-light lenses are not a myopia-control treatment. If your child needs glasses, the money is better spent on the right prescription, worn full time. The same goes for eye exercises and supplements: none has trial evidence for slowing the growth of the eye.

Is low-dose atropine being studied in Malaysian children?

Yes. A randomised trial called ATOM-MY, registered on ClinicalTrials.gov as NCT07329777, is recruiting children aged five to ten at two university hospitals in Kuala Lumpur. It compares 0.025 percent atropine drops with placebo, where neither the family nor the examiner knows who is on the real drop, with a two-year follow-up. It began in September 2025 and its first results are not due before 2027, so it has nothing to report yet. I mention it because it means low-dose atropine is being studied here, in Malaysian children, rather than only imported on trust.

How much does myopia control cost in Malaysia?

The figures set by law are the ones I can give you. At a government hospital eye clinic a Malaysian citizen pays a registration charge of RM5 for a specialist visit, or RM30 for a first visit on a private referral, and needs a referral from a klinik kesihatan or GP. At a private hospital or similar facility the specialist consultation fee is regulated in a range from RM80 to RM235. The drops, lenses and follow-up tests are charged separately, and I do not quote figures for them here: they differ from clinic to clinic and change over time. Ask any clinic for a written estimate before you start.

How will I know if the treatment is working?

By the rate of change, not by the blur going away. Your doctor repeats the prescription measurement with focusing-relaxing drops, and where the clinic can, measures the length of the eye, and compares the climb with what it was before. A prescription that still rises a little on treatment is not a failure; the aim is a slower climb than untreated, and it takes time, usually a year of measurements, to judge that fairly.

Does my child still need outdoor time if they are on drops or special lenses?

Yes, but be clear about why. Outdoor time has good evidence for delaying the start of short-sightedness, so it matters most for the younger siblings who are not yet myopic. For a child already short-sighted, the evidence that it slows the climb is weak, so it is not a substitute for treatment. It remains free, good for sleep and mood, and part of every plan I write; it is simply not the part doing the slowing.

References

American Academy of Ophthalmology · Myopia control in children · www.aao.org
American Academy of Ophthalmology · Reducing the global burden of myopia by delaying onset and slowing progression (Task Force on Myopia clinical statement, 2021) · www.aao.org
Yam JC et al. · Low-Concentration Atropine for Myopia Progression (LAMP) Study, Ophthalmology 2019 (0.05%, 0.025% and 0.01% atropine versus placebo) · pubmed.ncbi.nlm.nih.gov
American Academy of Ophthalmology EyeWiki · Myopia (treatment evidence and rebound after stopping atropine) · eyewiki.aao.org
American Academy of Ophthalmology · Preventing childhood myopia with sunshine and outdoor time · www.aao.org
American Academy of Ophthalmology · Screen use for kids (no evidence that screen light damages eyes) · www.aao.org
AAPOS · Glasses for children (glasses do not weaken a child's eyes) · aapos.org
ClinicalTrials.gov · NCT07329777, Atropine in the Treatment of Myopia Study in Malaysia (ATOM-MY) · clinicaltrials.gov
Hospital Miri, Ministry of Health Malaysia · Charges and payment (public hospital registration charges) · jknsarawak.moh.gov.my
CodeBlue · Schedule 13 specialist consultation fee range under the Private Healthcare Facilities and Services Act, 6 December 2019 · codeblue.galencentre.org

By Dr Chan Li Yen. General information only. It does not replace a consultation. If you are worried about your child's eyes or vision, please see an eye doctor.